Evidence map›Paper›PMID 32328071›Full record

ArticleFrontiers in immunology2020

Multiplex T Cell Stimulation Assay Utilizing a T Cell Activation Reporter-Based Detection System.

Sarah E Mann, Zhicheng Zhou, Laurie G Landry, Amanda M Anderson, Aimon K Alkanani, Jeremy Fischer, Mark Peakman, Roberto Mallone, Kristen Campbell, Aaron W Michels and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. De novo identification of CD4Nature methods · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Antibiotics (Basel, Switzerland) · 2022
    Article
  12. Article
  13. Article
  14. Frontiers in endocrinology · 2022
    Review
  15. Article
  16. Human islet T cells are highly reactive to preproinsulin in type 1 diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  17. Vaccines · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Sarah E MannBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Zhicheng ZhouCNRS, INSERM, Institut Cochin, Université de Paris, Paris, France.
Laurie G LandryBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Amanda M AndersonBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Aimon K AlkananiBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Jeremy FischerBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Mark PeakmanDepartment of Immunobiology, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Roberto MalloneCNRS, INSERM, Institut Cochin, Université de Paris, Paris, France.
Kristen CampbellDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, United States.
Aaron W MichelsBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
Maki NakayamaBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, United States.
University of Colorado Denver · USInserm · FRInstitut Cochin · FRKing's College London · GB

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LORI SUSSEL · 2020 to 2026
$10.8M
Multiple Autoantigens/Multiple Epitopes of Type 1DMR01DK032083 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W · 1986 to 2025
$6.9M
Molecular Dissection of Insulin Targeting in Anti-Islet AutoimmunityR01DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS, Maki Nakayama · 2013 to 2026
$5.3M
Insulin Specific T Cell Response Shaped by Diabetes Protective MHC Class II MoleculesR01DK108868 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI AARON W MICHELS · 2017 to 2026
$3.6M
Analysis of human autoreactive T cell receptors in vivoUC4DK104223 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GILL, RONALD G · 2014 to 2014
$2.0M
Insulin Specific T and B cells in Type 1 DiabetesDP3DK110845 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CAMBIER, JOHN C, MICHELS, AARON W · 2016 to 2016
$1.7M
Autoantigens targeted by CD8 T cells in type 1 diabetes: from islets to bloodR56DK099317 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI MICHELS, AARON W, NAKAYAMA, MAKI · 2019 to 2019
$194k
NCATS NIH HHS UL1 TR002535NIDDK NIH HHS DP3 DK110845NIDDK NIH HHS P30 DK116073NIDDK NIH HHS R01 DK032083NIDDK NIH HHS R01 DK099317NIDDK NIH HHS R01 DK108868NIDDK NIH HHS R56 DK099317NIDDK NIH HHS UC4 DK104223
6 · The paper itself

Abstract

Recent advancements in single cell sequencing technologies allow for identification of numerous immune-receptors expressed by T cells such as tumor-specific and autoimmune T cells. Determining antigen specificity of those cells holds immense therapeutic promise. Therefore, the purpose of this study was to develop a method that can efficiently test antigen reactivity of multiple T cell receptors (TCRs) with limited cost, time, and labor. Nuclear factor of activated T cells (NFAT) is a transcription factor involved in producing cytokines and is often utilized as a reporter system for T cell activation. Using a NFAT-based fluorescent reporter system, we generated T-hybridoma cell lines that express intensely fluorescent proteins in response to antigen stimulation and constitutively express additional fluorescent proteins, which serve as identifiers of each T-hybridoma expressing a unique TCR. This allows for the combination of multiple T-hybridoma lines within a single reaction. Sensitivity to stimulation is not decreased by adding fluorescent proteins or multiplexing T cells. In multiplexed reactions, response by one cell line does not induce response in others, thus preserving specificity. This multiplex assay system will be a useful tool for antigen discovery research in a variety of contexts, including using combinatorial peptide libraries to determine T cell epitopes.

Indexed as

AnimalsCD3 ComplexCD4-Positive T-LymphocytesEpitopes, T-LymphocyteGenes, ReporterGenetic VectorsHybridomasImmunizationImmunoassayLymphocyte ActivationMiceNFATC Transcription FactorsReceptors, Antigen, T-CellRetroviridaeSignal TransductionCD3 ComplexEpitopes, T-LymphocyteNFATC Transcription FactorsReceptors, Antigen, T-Cellantigensepitopesmultiplex assayreporterT cell receptors

Identifiers

PMID32328071
PMCPMC7160884
OpenAlexW3015687710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.